ALTITUDE‐AD: Cost Savings Using a pTau217 Screening Assay in an Ongoing Phase 2 Study of Sabirnetug in Early Alzheimer's Disease

Participants tested by amyloid PET or CSF Aβ42/40 were enriched for meeting amyloid-based inclusion criteria and the screening cost was reduced by approximately US $10 million (∼40%). Additionally, the pTau217 screening strategy helped reduce the unnecessary burden of PET scans and LP procedures for potential participants.